Unintended adverse events ‐ not reported · children aged 5 years and under
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost‐effectiveness ‐ not reported · children aged 5 years and under
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term impact (< 12 months) unintended adverse events · children aged 5 years and under
1 finding from 1 review
Short‐term impact (< 12 months) child fruit and vegetable intake · children aged 5 years and under
1 finding from 1 review
Cost‐effectiveness · children aged 5 years and under
1 finding from 1 review
Short‐term impact (< 12 months) unintended adverse events · children aged 5 years and under
1 finding from 1 review
Short‐term impact (< 12 months) child fruit and vegetable intake · children aged 5 years and under
1 finding from 1 review
Cost‐effectiveness ‐ not reported · children aged 5 years and under
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term impact (< 12 months) unintended adverse events ‐ not reported · children aged 5 years and under
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: range 15 to 31 days · people with cardiogenic shock or low cardiac output syndrome
Levosimendan showed no clear difference in all‐cause short‐term mortality: range 15 to 31 days compared with dobutamine (low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: 1 month · adults with low cardiac output syndrome
It is very uncertain whether enoximone changes all‐cause short‐term mortality: 1 month compared with dobutamine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality: 60 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause long‐term mortality: 60 days compared with norepinephrine (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: at intensive care unit · adults with cardiogenic shock
It is very uncertain whether dopamine‐milrinone changes all‐cause short‐term mortality: at intensive care unit compared with dopamine‐dobutamine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found